Navigation Links
Neurocrine Announces Top-Line Results of Corticotropin Releasing Factor Antagonist GSK561679 for Treatment of Major Depressive Disorder
Date:9/14/2010

gest pharmaceutical markets in the world including endometriosis, anxiety, depression, pain, diabetes, irritable bowel syndrome, insomnia, and other neurological and endocrine related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com

In addition to historical facts, this press release may contain forward-looking statements that involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with Neurocrine's business and finances in general, as well as risks and uncertainties associated with the Company's CRF program and Company overall. Specifically, the risks and uncertainties the Company faces with respect to the Company's CRF program include, but are not limited to, risk that GSK may terminate its development of GSK561679 and/or its collaboration with the Company;  risk that the ongoing GSK561679 clinical trials will fail to demonstrate that GSK561679 is safe and effective; risk that the Company's CRF program backup product candidates will not prove suitable for clinical development; risk that the Company will be unable to raise additional funding required to complete development of its CRF program product candidates; risk associated with the Company's dependence on corporate partners for future clinical development, commercial manufacturing and marketing and sales activities; uncertainties relating to patent protection and intellectual property rights of third parties; risks and uncertainties relating to competitive products and technological changes that may limit demand for the Company's CRF program products; and the other risks described in the Company's report on Form 10-K for the year ended December 31, 2009 and reports on Form 10-Q for the quarter ende
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Neurocrine Biosciences Announces Conference Call and Webcast to Report Second Quarter 2010 Financial Results
2. -- Neurocrine Announces a Second Corporate Collaboration Within Twenty-Four Hours -- Neurocrine Biosciences Announces a Worldwide Collaboration With Boehringer Ingelheim to Research and Develop GPR119 Agonists for Type II Diabetes
3. Neurocrine Biosciences to Present at the Deutsche Bank 35th Annual Health Care Conference
4. Neurocrine Biosciences to Present at the 30th Annual Cowen & Co. Health Care Conference
5. Neurocrine Biosciences, Inc. Prices Common Stock Offering
6. Neurocrine Announces Proposed Public Offering of Common Stock
7. Neurocrine Advances VMAT2 Inhibitor Program
8. Neurocrine Biosciences to Present at the 21st Annual Piper Jaffray Health Care Conference
9. Neurocrine Biosciences Reports Third Quarter 2009 Results
10. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2009 Financial Results
11. Neurocrine Biosciences Presents Elagolix Data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Research and Markets ... the "Dental Consumables Market - Global Industry ... - 2018" report to their offering. ... ) Dental consumables are products which are ... impairments, for tooth restoration and in treatment of ...
(Date:1/15/2014)... , Jan. 15, 2014  Novation, the leading ... company, awarded several new IT value-added reseller (VAR) ... hospital organizations with IT goods and services at ... agreements, as well as value-added services such as ... New Novation agreements were awarded to ...
(Date:1/15/2014)... DUBLIN , January 15, 2014 ... that it has waived the Office of Fair Trading (OFT) ... the outstanding shares of ViroPharma Incorporated (NASDAQ: VPHM).   ... no longer conditional on OFT approval, and Shire expects to ... currently scheduled expiration time, subject to the satisfaction of all ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... Top-Line Data Expected in the Third Quarter --, ... VIAP ), a biotechnology company focused on the development ... that,it has completed the last patient visit in its ... be analyzed to determine,VIA-2291,s effect on inflammation, and the ...
... Modigene,s CTP Technology for Extending ... of Action of Therapeutic Proteins -, NES-ZIONA, Israel, ... noted the successful completion of a Phase,III clinical trial ... uses the naturally occurring CTP,peptide to extend the duration ...
Cached Medicine Technology:VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 4VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 5Modigene Platform Validated in Independent Phase III Trial of CTP Technology 2Modigene Platform Validated in Independent Phase III Trial of CTP Technology 3
(Date:4/14/2014)... treat children with uncomplicated acute appendicitis is a reasonable ... fewer missed school days, according to a pilot study. ... Hospital and published online April 12 in the ... the first prospective study on nonoperative management of acute ... , Researchers enrolled 77 patients age 7 to 17 ...
(Date:4/14/2014)... 2014, Perth, Australia. Drug discovery company Proteomics International ... of a companion diagnostic (CDx) test with the ... The research team authenticated the panel of biomarkers ... samples. Seven biomarkers were validated at high stringency ... The mass spectrometry data was then cross-validated using ...
(Date:4/14/2014)... 2014) When it comes to the cost and ... Patients get the best care when they are treated ... extensive experience in their current job, according to a ... and Columbia Business School. The study was published in ... Applied Economics . , The review of more ...
(Date:4/13/2014)... STANFORD, Calif. A low-cost empowerment program for ... and sexual harassment of these girls, who live ... and are frequently attacked, a large new study ... Stanford University School of Medicine, Lucile Packard Children,s ... No Worldwide, validated the program,s effectiveness in combating ...
(Date:4/11/2014)... the processes that control brain cell production could pave ... brain-related disorders. , Scientists have gained new understanding of ... how and when nerve and brain cells are formed ... and keeps it healthy. Their findings could help explain ... which is a fundamental characteristic of many diseases including ...
Breaking Medicine News(10 mins):Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4
... if parent, sibling has the movement disorder, study shows , ... of people who have restless legs syndrome are also more ... , The authors of the study, which is published in ... the findings will raise awareness of the condition for both ...
... ... syndrome , ... 2010 -- One person can make a difference, one dollar at a time: that’s the ... center for people with Trisomy 21 (better known as Down syndrome). Launched one week ago ...
... French . , Neurological research and clinical ... London and McGill University of Montreal entered an agreement ... field. Sir Keith O,Nions, Rector of Imperial, and Heather ... to sign the partnership documents, which will consolidate existing ...
... ... Sprint 4G, CradlePoint MBR1200 Router makes instant Internet access simple for small or remote ... , ... (PRWEB) May 10, 2010 -- Sprint (NYSE: S) has certified CradlePoint’s MBR1200 Failsafe Gigabit ...
... Rockville, Md., May 10, 2010 To promote ... labelsand to address the widespread problem of patient ... the U.S. Pharmacopeial Convention (USP) recently issued a ... on dispensed prescription packaging. The recommendations are patient-centered, ...
... monitored with measurement devices implanted inside a living body. ... aware of the presence of the implant. An example ... that has long since become standard treatment for heart ... of Technology (TUT) believes that the next tech-savvy generation ...
Cached Medicine News:Health News:Restless Legs Syndrome Can Have Family Ties 2Health News:Charity Asks for $1 2Health News:Trans-Atlantic agreement a boost to neuroscience research 2Health News:CradlePoint Router and Mobile Broadband Adapter Pair With Sprint 4G to Create Instant Offices, Business Continuity Solutions 2Health News:CradlePoint Router and Mobile Broadband Adapter Pair With Sprint 4G to Create Instant Offices, Business Continuity Solutions 3Health News:CradlePoint Router and Mobile Broadband Adapter Pair With Sprint 4G to Create Instant Offices, Business Continuity Solutions 4Health News:CradlePoint Router and Mobile Broadband Adapter Pair With Sprint 4G to Create Instant Offices, Business Continuity Solutions 5Health News:CradlePoint Router and Mobile Broadband Adapter Pair With Sprint 4G to Create Instant Offices, Business Continuity Solutions 6Health News:Panel recommends standardizing prescription container labeling 2Health News:Panel recommends standardizing prescription container labeling 3Health News:Panel recommends standardizing prescription container labeling 4Health News:Vital functions monitored with wearable and implantable devices 2Health News:Vital functions monitored with wearable and implantable devices 3
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
This unit is the finest standalone handswitch bipolar unit available....
...
...
Medicine Products: